A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Reduction seen in risk for readmission, wound dehiscence, and hematoma, but no significant differences seen in rates of infection, bleeding ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

GLP-1 RA drugs help treat diabetes by weight loss, improving blood glucose levels and increasing insulin sensitivity, low ...

The results also showed that the patients taking the GLP-1 RA drugs have a 12 per cent lower risk of hospital re-admission ...

Patients taking the anti-obesity drugs had about 12% lower risk of hospital re-admission within a month of surgery, compared ...

Taking the 'GLP-1 receptor agonist' class of anti-obesity drugs is related with lower rates of post-surgery complications in people with diabetes, according to a study. GLP-1 receptor agonist, or ...